Vortioxetine in the treatment of major depressive disorder

References

• Sanchez C , AsinKE, ArtigasF. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol. Therapeut. doi:10.1016/j.pharmthera.07.001 ( Epub ahead of print).
   Web of Science ®Google Scholar
• Guilloux JP , Mendez-DavidI, PehrsonAet al. Antidepressant and anxiolytic potential of the multimodal antidepressant Vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology73, 147e159 (2013).
   Web of Science ®Google Scholar
• Bang-Andersen B , RuhlandT, J⊘rgensenMet al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem.54, 3206–3221 (2011).
   PubMed Web of Science ®Google Scholar
• Ballaz SJ , AkilH, WatsonSJ. The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behaviour. Neuroscience149, 192–202 (2007).
   PubMed Web of Science ®Google Scholar
• Westrich L , PerhsonA, ZhongHet al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (LuAA21004) at human and rat targets. Int. J. Psychiatry Clin. Pract.16(Suppl. 1), 47 (2012).
   Google Scholar
• M⊘rk A , PehrsonA, BrennumLTet al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J. Pharmacol. Exp. Ther.340, 666–675 (2012).
   PubMed Web of Science ®Google Scholar
• Jensen JB , du JardinKG, SongDet al. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur. Neuropsychopharmacol.24, 148–159 (2014).
   PubMed Web of Science ®Google Scholar
• Du Jardin KG , JensenJB, SanchezC, PehrsonAL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur. Neuropsychopharmacol.24, 160–171 (2014).
   PubMed Web of Science ®Google Scholar
• Stenkrona P , HalldinC, LundbergJ. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (LuAA21004). A PET study in control subjects. Eur. Neuropsychopharmacol.23, 1190–1198 (2013).
   PubMed Web of Science ®Google Scholar
• Areberg J , Luntang-JensenM, S⊘gaardB, NilausenDØ. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin. Pharmacol. Toxicol.110, 401–404 (2012).
   PubMed Web of Science ®Google Scholar
• Meyer JH , WilsonAA, SagratiSet al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry161, 826–835 (2004).
   PubMed Web of Science ®Google Scholar
• Alvarez E , PerezV, DragheimM, LoftH, ArtigasF. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int. J. Neuropsychopharmacol.15, 589–600 (2012).
   PubMed Web of Science ®Google Scholar
• Baldwin DS , LoftH, DragheimM. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of vortioxetine in acute treatment of major depressive disorder. Eur. Neuropsychopharmacol.22, 482–491 (2012).
   PubMed Web of Science ®Google Scholar
• Henigsberg N , MahableshwarkarAR, JacobsenP, ChenY, ThaseME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J. Clin. Psychiatry73, 953–959 (2012).
   PubMed Web of Science ®Google Scholar
• Areberg J , S⊘gaardB, H⊘jerAM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin. Pharmacol. Toxicol.111, 198–205 (2012).
   PubMed Web of Science ®Google Scholar
• Hvenegaard MG , Bang-AndersenB, PedersenH, J⊘rgensenM, PüschlA, DalgaardL. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab. Dispos.40, 1357–1365 (2012).
   PubMed Web of Science ®Google Scholar
• Uldam HK , JuhlM, PedersenH, DalgaardL. Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004. Drug Metab. Disposition39, 2264–2274 (2011).
   PubMed Web of Science ®Google Scholar
• Chen G , LeeR, H⊘jerAM, BuchbjergJK, SerenkoM, ZhaoZ. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin. Drug Investig.33, 727–736 (2013).
   PubMed Web of Science ®Google Scholar
• Khin NA , ChenY-F, YangY, YangP, LaughrenTP. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J. Clin. Psychiatry72, 464–472 (2011).
   PubMed Web of Science ®Google Scholar
• Lane P . Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharmaceut. Statist.7, 93–106 (2008).
   PubMed Web of Science ®Google Scholar
• Siddiqui O , HungHM, O’NeillR. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J. Biopharm. Stat.19, 227–246 (2009).
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR , JacobsenPL, ChenY. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine versus placebo for 8 weeks in adults with major depressive disorder. Curr. Med. Res. Opin.29, 217–226 (2013).
   PubMed Web of Science ®Google Scholar
• Jain R , MahableshwarkarAR, JacobsenPL, ChenY, ThaseME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int. J. Neuropsychopharmacol.16, 313–321 (2013).
   PubMed Web of Science ®Google Scholar
• Boulenger JP , LoftH, OlsenCK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int. Clin. Psychopharmacol.29, 138–149 (2013).
   Web of Science ®Google Scholar
• Mahableshwarkar AR , JacobsenPL, SerenkoM, ChenY, TrivediM. A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD. Presented at: 166th Annual Meeting of the American Psychiatric Association (APA), San Francisco, CA, USA, 18–22 May 2013.
   Google Scholar
• Mahableshwarkar A , JacobsenPL, SerenkoM, ChenY, TrivediM. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine (LuAA21004) in adults with major depressive disorder. Presented at: 166th Annual Meeting of the American Psychiatric Association (APA). San Francisco, CA, USA, 18–22 May 2013.
   Google Scholar
• Jacobsen P , MahableshwarkarAR, SerenkoM, ChanS, TrivediM. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10mg and 20mg in adults with major depressive disorder. Presented at: 166th Annual Meeting of the American Psychiatric Association (APA). San Francisco, CA, USA, 18–22 May 2013.
   Google Scholar
• Katona C , HansenT, OlsenCK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol.27, 215–223 (2012).
   PubMed Web of Science ®Google Scholar
• McIntyre RS , LophavenS, OlsenCK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol.17, 1557–1567 (2014).
   PubMed Web of Science ®Google Scholar
• Montgomery SA , NielsenRZ, PoulsenLH, HäggströmL. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum. Psychopharmacol.29, 470–482 (2014).
   PubMed Web of Science ®Google Scholar
• Koesters M , GuaianaG, CiprianiA, BeckerT, BarbuiC. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br. J. Psychiatry203, 179–187 (2013).
   PubMed Web of Science ®Google Scholar
• Taylor D , SparshattA, VarmaS, OlofinjanaO. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ348, g1888 (2014).
   PubMed Web of Science ®Google Scholar
• Pae CU , WangSM, HanCet al. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J. Psychiatry Neurosci.39(6), 140120 (2014).
   Google Scholar
• Llorca PM , LançonC, BrignoneMet al. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Curr. Med. Res. Opin.30(12), 2589–2606 (2014).
   PubMed Web of Science ®Google Scholar
• Baldwin DS , LoftH, JacobsenP, FloreaI. The efficacy of vortioxetine in treating patients with severe depression or with depression and high level of anxiety symptoms. Poster presented at: 27th ECNP Congress. Berlin, Germany, 18–21 October 2014 ( Poster).
   Google Scholar
• Baldwin DS , HansenT, FloreaI. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr. Med. Res. Opin.28, 1717–1724 (2012).
   PubMed Web of Science ®Google Scholar
• Alam MY , JacobsenPL, ChenY, SerenkoM, MahableshwarkarAR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int. Clin. Psychopharmacol.29, 36–44 (2014).
   PubMed Web of Science ®Google Scholar
• Boulenger JP , LoftH, FloreaI. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J. Psychopharmacol.26, 1408–1416 (2012).
   PubMed Web of Science ®Google Scholar
• Baldwin DS , SerenkoM, PaloW, LophavenS, MatzJ. The safety and tolerability of vortioxetine (Lu AA21004) in the treatment of adults with major depressive disorder. Int. Clin. Psychiatry Clin. Pract.17(Suppl. 2), S16–S17 (2013).
   PubMedGoogle Scholar
• Rosenbaum JF , FavaM, HoogSL, AscroftRC, KrebsWB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol. Psychiatry44, 77–87 (1998).
   PubMed Web of Science ®Google Scholar
• Posner K , BrownGK, StanleyBet al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry168, 1266–1277 (2011).
   PubMed Web of Science ®Google Scholar
• Baldwin DS , MahableshwarkarAR, ChronesL, PaloW, MatzJ. The safety and tolerability of vortioxetine in treating adults with major depressive disorder after 52weeks of open-label treatment. Poster presented at: 27th ECNP Congress. Berlin, Germany, 18–21 October 2014.
   Google Scholar
• Garnock-Jones KP . Vortioxetine: a review of its use in major depressive disorder. CNS Drugs28, 855–874 (2014).
   PubMed Web of Science ®Google Scholar
• Bidzan L , MahableshwarkarAR, JacobsenP, YanM, SheehanDV. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur. Neuropsychopharmacol.22, 847–857 (2012).
   PubMed Web of Science ®Google Scholar
• Rothschild AJ , MahableshwarkarAR, JacobsenP, YanM, SheehanDV. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur. Neuropsychopharmacol.22, 858–866 (2012).
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR , JacobsenPL, ChenY, SimonJS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int. J. Clin. Pract.68, 49–59 (2014).
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR , JacobsenPL, Serenko, ChenY. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 mg and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum. Psychopharmacol.29, 64–72 (2014).
   PubMed Web of Science ®Google Scholar
• Baldwin DS , LoftH, FloreaI. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int. Clin. Psychopharmacol.27, 197–207 (2012).
   PubMed Web of Science ®Google Scholar
• Citrome L . Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number need to treat, number needed to harm, and likelihood to be helped or harmed?Int. J. Clin. Pract.68, 608–682 (2014).
   Web of Science ®Google Scholar
• Baldwin DS , FoongT. Antidepressant drugs and sexual dysfunction. Br. J Psychiatry202, 396–397 (2013).
   PubMed Web of Science ®Google Scholar
• McIntyre RS , ChaDS, SoczynskaJKet al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates and treatment interventions. Depress. Anx.30, 515–527 (2013).
   PubMed Web of Science ®Google Scholar
• Impey B , BaldwinDS. On ‘cognitive dysfunction’ as a novel target for antidepressant treatment. Hum. Psychopharmacol.28, 535–537 (2013).
   PubMed Web of Science ®Google Scholar
• Bora E , HarrisonBJ, YücelM, PantelisC. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol. Med.43, 2017–2026 (2013).
   PubMed Web of Science ®Google Scholar
• Mork A , MontezhinoLP, MillerSet al. Vortioxetine (LuAA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol. Biochem. Behav.105, 41–50 (2013).
   PubMed Web of Science ®Google Scholar
• Wallace A , PehrsonAL, SanchezC, MorilakDA. Vortioxetine restores learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int. J. Neuropsychopharmacol.17, 1695–1706 (2014).
   PubMed Web of Science ®Google Scholar
• Theunissen EL , StreetD, H⊘jerAM, VermeerenA, van OersA, RamaekersJG. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin. Pharmacol. Ther.93, 493–501 (2013).
   PubMed Web of Science ®Google Scholar